Jacobs Levy Equity Management, Inc Nektar Therapeutics Transaction History

Jacobs Levy Equity Management, Inc

$21.8 Billion
Q1 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,911,186 shares of NKTR stock, worth $2.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,911,186

Previous 3,404,165 43.86%

Holding current value

$2.37 Million

Previous $1.91 Million 6.77%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $731,559 - $1.43 Million	-1,492,979 Reduced 43.86%	1,911,186 $1.78 Million
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $630,243 - $855,330	-1,500,580 Reduced 30.59%	3,404,165 $1.91 Million
Q3 2023 Nov 16, 2023	BUY	$0.51 - $1.05 $17,476 - $35,980	34,267 Added 0.7%	4,904,745 $2.94 Million
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $1.19 Million - $2.32 Million	2,252,391 Added 86.03%	4,870,478 $2.82 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $30,232 - $148,799	47,238 Added 1.84%	2,618,087 $1.83 Million

Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $3.11 Million - $6.56 Million	1,532,920 Added 147.69%	2,570,849 $5.81 Million
Q3 2022 Nov 15, 2022	BUY	$3.04 - $5.14 $2.46 Million - $4.16 Million	809,966 Added 355.31%	1,037,929 $3.32 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $722,642 - $1.41 Million	227,963 New	227,963 $866,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $386,534 - $1.27 Million	-92,917 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $63,193 - $107,422	5,835 Added 6.7%	92,917 $1.26 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $805,125 - $1.16 Million	61,601 Added 241.75%	87,082 $1.56 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $97,038 - $119,829	5,874 Added 29.96%	25,481 $437,000
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $925,190 - $1.42 Million	-55,869 Reduced 74.02%	19,607 $392,000
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $20,579 - $24,834	-1,305 Reduced 1.7%	75,476 $1.28 Million
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $302,867 - $452,566	18,256 Added 31.19%	76,781 $1.27 Million
Q2 2020 Aug 17, 2020	BUY	$16.86 - $23.44 $986,731 - $1.37 Million	58,525 New	58,525 $1.36 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Nektar Therapeutics Transaction History